- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07363876
Effektiviteten av ultraljudsbehandling i kombination med intraartikulär injektion av kortikosteroid vid artrit
Effekten av ultraljud i kombination med intraartikulär injektion av kortikosteroid för artrit
This study investigates whether ultrasound therapy applied prior to intra-articular corticosteroid injection can enhance the treatment efficacy for patients with joint arthritis and assess its safety. Adult patients diagnosed with arthritis in the limbs who are indicated for corticosteroid injection are eligible, while patients with joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis are excluded.
Ultrasound therapy is a valuable physical therapy tool for musculoskeletal diseases, producing therapeutic effects through thermal and non-thermal mechanisms. It can improve tissue extensibility, reduce joint stiffness, increase local blood flow, enhance metabolism during tissue repair, and facilitate drug absorption. This study evaluates whether applying ultrasound before intra-articular corticosteroid injection improves therapeutic outcomes in patients with arthritis, and assesses the safety of this combined intervention. Patients aged 18 or older, diagnosed with limb arthritis, and indicated for corticosteroid injection are eligible. Exclusion criteria include joint replacement, hip joint involvement, gout, infectious arthritis, or local cellulitis at the treatment site.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Kuo-Lung Lai, MD
- Telefonnummer: +886-4-2359-2525
- E-post: kllaichiayi@yahoo.com.tw
Studieorter
-
-
-
Taichung, Taiwan, 407219
- Rekrytering
- Taichung Veterans General Hospital
-
Kontakt:
- Kuo-Lung Lai, MD
- Telefonnummer: +886-4-2359-2525
- E-post: kllaichiayi@yahoo.com.tw
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adults aged 18 years or older.
- Diagnosed with arthritis in the limbs.
- Inadequate response to or contraindication for oral anti-inflammatory medications.
- Assessed by a physician as requiring intra-articular corticosteroid injection.
Exclusion Criteria:
- History of joint replacement (prosthetic joint) in the affected area.
- Hip joint involvement.
- Diagnosis of gout.
- Infectious arthritis.
- Presence of cellulitis at the treatment site.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: ultraljudsbehandling i kombination med intraartikulär kortikosteroidinjektion
|
Therapeutic Ultrasound (TUS) is a non-invasive treatment widely used in physical medicine and rehabilitation for musculoskeletal conditions. Since its introduction in the mid-20th century, TUS has gained popularity in clinical practice due to its ability to penetrate tissues, target treatment areas precisely, and exhibit minimal side effects. This study aims to investigate the mechanisms of action, clinical efficacy, and safety of therapeutic ultrasound in musculoskeletal therapy. Injection of triamcinolone (3-50 mg depending on joint size) into the affected joint. Administered once per participant. |
|
Aktiv komparator: kortikosteroid intraartikulär injektion
|
Injection of triamcinolone (3-50 mg depending on joint size) into the affected joint. Administered once per participant. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Reduction in Synovial Swelling Area Assessed by Joint Ultrasound
Tidsram: From enrollment to the end of treatment at 2 weeks
|
Synovial swelling area (pixels) assessed by joint ultrasound. A treatment response is defined as a ≥50% reduction in synovial swelling area from baseline. |
From enrollment to the end of treatment at 2 weeks
|
|
Change in Power Doppler (PD) Score of the Target Joint
Tidsram: From enrollment to the end of treatment at 2 weeks
|
Power Doppler (PD) score (range 0-3) of the target joint assessed by joint ultrasound. A treatment response is defined as a PD score of 0 at 2 weeks post-treatment. |
From enrollment to the end of treatment at 2 weeks
|
|
Change in Pain Visual Analogue Scale (VAS)
Tidsram: From enrollment to the end of treatment at 2 weeks
|
Pain intensity assessed using a visual analogue scale (VAS 0-10). A treatment response is defined as a ≥50% reduction in VAS score from baseline or a VAS score ≤1 at 2 weeks post-treatment. |
From enrollment to the end of treatment at 2 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Absence of Synovitis Recurrence Based on Power Doppler (PD) Score
Tidsram: From enrollment to 3 months post-treatment
|
Absence of synovitis recurrence assessed by Power Doppler (PD) ultrasound. Recurrence is defined as any increase in PD score compared with the 2-week post-treatment assessment. |
From enrollment to 3 months post-treatment
|
|
Absence of Synovial Swelling Recurrence on Gray-Scale Ultrasound
Tidsram: From enrollment to 3 months post-treatment
|
Absence of synovial swelling recurrence assessed by gray-scale ultrasound. Recurrence is defined as an increase in synovial swelling area of ≥20% compared with the 2-week post-treatment assessment. |
From enrollment to 3 months post-treatment
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Kuo-Lung Lai, MD, Taichung Veterans General Hospital (TaichungVGH)
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TCVGH-1150801B
- CF25511A (Annan identifierare: TCVGH IRB)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .